Rumors about a potential new phase of the Pfizer/AstraZeneca takeover saga just won't go away, with all the talk giving the U.K. pharma's share price a lift this week.
The story about a potential new takeover offer for AstraZeneca by Pfizer will not die.
Look out, Sanofi. Pfizer's Clostridium difficile candidate has just nabbed an FDA fast-track designation that should help it pick up some ground in the race to bring the first vaccine for the disease to market.
Earlier this year, when Pfizer made a play for rival pharma giant AstraZeneca, CEO Ian Read listed the British drugmaker's vaccines portfolio as a motivating factor. Now, rumors are swirling that the company could be eyeing Actavis as a backup plan. On the one hand, the New Jersey generics maker lacks vaccines offerings. And on the other, with the recent developments affecting Pfizer's unit, how much does that matter?
Let the speculation continue: The window to another Pfizer-AstraZeneca bidding round is now open, per U.K. takeover rules.
Pfizer isn't among the leaders in the hot immuno-oncology field. But the company is friends with one of them--Merck. And now, Pfizer has tied yet another cancer treatment to Merck's IO coattails.
Merck and Pfizer have struck a deal to add the immuno-oncology superstar pembrolizumab to Xalkori for ALK-positive cases of advanced non-small cell lung cancer.
Months removed from an intercontinental M&A dance that polarized investors and paralyzed executives, Pfizer and AstraZeneca will soon be free to start talking about a deal once more, provided the latter company is interested.
Pfizer and Bristol-Myers Squibb's Eliquis has been lagging since launch time, trailing behind predecessors Pradaxa and Xarelto. But lately, the drugmakers' efforts have been paying off when it comes to market share, and a new indication may help keep the ball rolling.
Eli Lilly has posted a superior therapeutic profile for its experimental late-stage psoriasis drug ixekizumab when compared with Pfizer's Enbrel in a head-to-head study.